A Randomized, Multicenter, Placebo and Active-controlled, Single-dose, 4-period, Crossover Study to Evaluate the Bronchodilating Effect of SYMBICORT pMDI Versus Advair Diskus and Ventolin HFA.

NCT00646009 Phase 3 COMPLETED

The purpose of this study is to compare the early onset of effect of Symbicort compared to Advair Diskus and Ventolin in adults with asthma

Details

Lead sponsor	AstraZeneca
Phase	Phase 3
Status	COMPLETED
Enrolment	48
Start date	2003-03
Completion	2003-08

Conditions

• Asthma

Interventions

• budesonide/formoterol
• fluticasone/salmeterol
• albuterol

Primary outcomes

• FEV1 3 minutes post dose — 4 assessments across 4 visits whilst on treatment (visits may be between 3 and 14 days apart)